Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.56% | 6.64% | -4.72% | -5.70% | -270.17% |
| Total Depreciation and Amortization | 34.37% | -3.34% | 53.54% | 53.08% | 64.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.18% | -84.12% | -118.44% | -105.23% | 104,284.21% |
| Change in Net Operating Assets | 121.40% | 18.46% | 62.60% | -34.91% | -794.32% |
| Cash from Operations | 67.55% | -23.70% | -2.87% | -111.04% | -122.09% |
| Capital Expenditure | 95.24% | -163.84% | -894.78% | -1,018.27% | -198.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 91.10% | -- | -- | -- |
| Cash from Investing | -100.04% | 87.34% | -894.78% | -1,018.27% | 37,359.35% |
| Total Debt Issued | -- | 800.00% | -- | -- | -- |
| Total Debt Repaid | 34.33% | 130.41% | -85.11% | -164.74% | -170.48% |
| Issuance of Common Stock | -- | -- | -100.00% | -98.68% | 1,654.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 1.73% | -- | 100.00% | -- |
| Cash from Financing | 50.76% | -90.73% | -141.76% | -127.67% | -242.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.67% | -82.64% | -86.34% | -784.87% | 736.54% |